Mayo Clinic Study Uses Phenomix AI Algorithm to Predict GLP-1 Side Effects, Advancing Personalized Obesity Care and Drug Development

Study presented at DDW 2025 finds genetic risk scores can identify patients at higher risk of nausea from GLP-1 therapies, supporting the development of more targeted treatment decisions and advancing pharmaceutical R&D. MENLO PARK, Calif., May 7, 2025 /PRNewswire/ — Phenomix Sciences…